Abstract Library

#2870 When It Comes to the Diagnostic of Neuroendocrine Neoplasms (NEN), Not All Markers and Clones Were Made Equal. Assessment of 5 Makers in 466 NEN from 10 Anatomical Sites

Introduction: Histological diagnostic of neuroendocrine neoplasms (NEN) relies on morphological criteria and expression of several neuroendocrine marker assessed by immunohistochemistry. Systematic large evaluation of classical (chromogranin A (chrA), synaptophysin (Syn), CD56) and emerging (chromogranin B (chrB), INSM1) markers are lacking.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cros J

Authors: Mamodaly M, Chen R, Cazes A, Guedj N, Deschamps L,

Keywords: Neuroendocrine markers, Chromogranin A, Chromogranin B, INSM1,

#2267 Large Cell Neuroendocrine Carcinoma of the Lung: Single-Centre Retrospective Cohort Study

Introduction: Large Cell Neuroendocrine Carcinoma (LCNEC) is a rare lung tumour, diagnosed based on high-grade features, presence of neuroendocrine morphology and immunohistochemical evidence of neuroendocrine markers. LCNEC was grouped with the pulmonary neuroendocrine carcinomas in 2015 WHO classification.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Martins Branco D, Cunha F, Claro I, Almodovar T,

Keywords: LCNEC,

#2257 Poorly Differentiated Neuroendocrine Carcinomas of the Colon: A Clinicopathological Study

Introduction: Neuroendocrine carcinomas (NEC) of the colon and rectum are aggressive and rare tumours. The Digestive Tract WHO classification 2010 defines the entity of large cell NEC (LCNEC) in contrast to small cell NEC (SCNEC).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Boeck I

Authors: Boeck I, Weihe E, Krieg A, Gabbert H, Raffel A,

Keywords: GEP-NEC, LCNEC, Colonic NEC,

#1592 Primary Neuroendocrine Carcinoma of the Breast: A Diagnostic Approach to the Special Type of Breast Malignancy

Introduction: WHO classification from 2003 defines primary neuroendocrine carcinomas (NEC) of the breast as a group of tumors with expression of neuroendocrine markers in more than 50% of tumor cells. In the current WHO classification this category is renamed to “carcinomas with neuroendocrine features” without defined clear-cut of the percentage of tumor cells positive for neuroendocrine markers.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Demirovic A

Authors: Demirović A, Vranic S, Skenderi F, Peric Balja M, Ulamec M,

Keywords: breast cancer, special types, carcinoma with neuroendocrine features, neuroendocrine markers,

#1551 Establishment and Characterization of Three GEP-NEC Cell Lines for In Vitro and In Vivo Studies

Introduction: To date chemotherapeutic concepts applying cisplatin/etoposide for the treatment of highly aggressive GEP-NEC do not provide convincing results. Thus, there is an urgent need for NEC cell line models that provide a reliable experimental system in identifying novel therapeutic targets.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Krieg A

Authors: Krieg A, Riemer J, Dizdar L, Mersch S, Anlauf M,

Keywords: GEP-NEC,